Testosterone Replacement Therapy in Advanced Chronic Kidney Disease
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
Muscle wasting is common in advanced chronic kidney disease (CKD) and adversely affects
morbidity and mortality. In 2/3 of males with advanced CKD serum testosterone (TT) levels are
reduced, and likely contributes to the wasting. As TT in relatively safe physiologic
replacement doses, increases muscle mass in otherwise normal TT deficient subjects, we
hypothesize that physiologic TT replacement will be effective in preventing and treating the
loss of muscle mass and function in CKD patients, will improve quality of life and may reduce
some cardiovascular disease (CVD) risk factors.